

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/728,055
		Filing Date	December 4, 2003
		First Named Inventor	George Mulligan
		Group Art Unit	1642
		Examiner Name	Reddig, Peter J.
		Attorney Docket Number	MPI02-202P1RNM
OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
/PR/	C1	Adams, Julian, et al., "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents," <i>Cancer Research</i> , Vol 59 (June 1, 1999) pp 2615-2622	
/PR/	C2	Adams, Julian, "Development of the Proteasome Inhibitor PS-341," <i>The Oncologist</i> , Vol. 7 (2002) pp 9-16	
/PR/	C3	Lightcap, Eric S., et al., "Proteasome Inhibition Measurements: Clinical Application," <i>Clinical Chemistry</i> , Vol. 46, No. 5 (2000) pp 673-683	
/PR/	C4	Hochwald, Steven N., et al., "Antineoplastic Therapy in Colorectal Cancer through Proteasome Inhibition," <i>The American Surgeon</i> , Vol. 69 (January 2003) pp 15-23	
/PR/	C5	Richardson, Paul G., et al., "A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma," <i>The New England Journal of Medicine</i> , Vol. 348, No. 26 (June 26, 2003) pp 2609-2617	
/PR/	C6	van de Vijver, Marc J., et al., "A Gene-Expression Signature as a Predictor of Survival in Breast Cancer," <i>The New England Journal of Medicine</i> , Vol. 347, No. 25 (Dec. 19, 2002) pp 1999-2009	
/PR/	C7	Barden, Catherine B., et al., "Classification of Follicular Thyroid Tumors by Molecular Signature: Results of Gene Profiling," <i>Clinical Cancer Research</i> , Vol. 9 (May 2003) pp 1792-1800	
/PR/	C8	Jiang, Xiaoyan, et al., "Ahl-1, a Novel Gene Encoding a Modular Protein with WD-40-Repeat and SH3 Domains, Is Targeted by the Ahl-1 and Mis-2 Provirus Integrations," <i>Journal of Virology</i> , Vol. 76, No. 18 (Sept. 2002) pp 9046-9059	
/PR/	C9	Jiang, Xiaoyan, et al., "Deregulated Expression in Ph+ Human Leukemias of AHI-1, a Gene Activated by Insertional Mutagenesis in Mouse Models of Leukemia," <i>Blood</i> , Vol. 103, No. 10 (May 15, 2004) pp 3897-3904	
Examiner Signature	/Peter Reddig/		Date Considered
			08/24/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/728,055
		Filing Date	December 4, 2003
		First Named Inventor	George Mulligan
		Group Art Unit	1642
		Examiner Name	Reddig, Peter J.
		Attorney Docket Number	MPI02-202P1RNM
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T²
/PR/	C10	Mulligan, George, et al., "Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib," <i>Blood</i> , Vol. 109, No. 8 (April 15, 2007) pp 3177-3188	
/PR/	C11	"Affymetrix GeneChip Human Genome U95 Set HG-U95A," March 11, 2002 (sequence) Genbank, Bethesda, MD, USA: National Center for Biotechnology Information, Accession No. XP002293987	
/PR/	C12	An, W. G., et al., "Protease inhibitor-induced apoptosis: accumulation of wt p53, p21 ^{WAF1/CIP1} , and induction of apoptosis are independent markers of proteasome inhibition," <i>Leukemia</i> , Vol. 14, No. 7 (July 2000) pp 1276-1283	
/PR/	C13	Aghajanian, Carol, et al., "A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies," <i>Clinical Cancer Research</i> , Vol. 8, No. 8 (August 2002) pp 2505-2511	
/PR/	C14	Zimmermann, Johann, et al., "Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1," <i>Oncogene</i> , Vol. 19, No. 25 (June 2000) pp 2913-2920	
Examiner Signature	/Peter Reddig/		Date Considered 08/24/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.